首页> 外文期刊>Robotics and Machine Learning >Critical Outcome Technologies Inc. Receives Second U.S. Patent for COTI-2
【24h】

Critical Outcome Technologies Inc. Receives Second U.S. Patent for COTI-2

机译:Critical Outcome Technologies Inc.获得COTI-2的第二项美国专利

获取原文
获取原文并翻译 | 示例
           

摘要

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced that patent numbern8,138,191 was granted by the United States Patent and Trademark Office (USPTO) relating to COTI-2,nthe Company's most advanced oncology drug candidate. This is the second patent granted for COTI-2nand is another major milestone as it adds new patent protection, which includes the synergistic effects ofncombination therapies comprised of COTI-2 and members of other classes of anti cancer agents.
机译:关键成果技术公司(Critical Outcome Technologies Inc.)(TSX VENTURE:COT)宣布,美国专利商标局(USPTO)授予了专利号为8,138,191的专利,该专利涉及该公司最先进的肿瘤候选药物COTI-2。这是授予COTI-2n的第二项专利,也是另一个重要的里程碑,因为它增加了新的专利保护,其中包括由COTI-2和其他类型的抗癌药物组成的联合疗法的协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号